EVALUATION OF SERUM AND SALIVARY CA-125 IN BREAST CANCER PATIENTS – AN ANALYTICAL STUDY
DOI:
https://doi.org/10.22159/ajpcr.2023.v16i4.46864Keywords:
Cancer antigen 125, Breast cancer, Enzyme-linked immunosorbent assay, Tumor markersAbstract
Objective: Breast cancer in females is very frequent nowadays both in developed and developing countries. Many tests both invasive and non-invasive are available for the diagnosis of cancer breast. Tumor markers are the substances that are associated with tumors and help in the detection and follow-up. Cancer antigen 125 (CA-125) is one of the tumor markers, the level of which increases in many tumors including breast cancer.
Methods: The present study was carried out to quantitatively measure its level by enzyme-linked immunosorbent assay in the serum and saliva of known breast cancer patients and comparing it with control groups.
Results: Statistically significant role of CA-125 in cases of breast cancer was ascertained over the control group and also positive correlation was found between serum and salivary values of CA-125.
Conclusion: We conclude that CA-125 can be used as tumor markers in breast cancer patients for evaluation and salivary samples are equally effective as serum samples and also are easy and safe to obtain.
Downloads
References
DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev 2015;24:1495-506. doi: 10.1158/1055-9965.EPI-15-0535, PMID 26359465
Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16. J Biol Chem 2001;276:27371-5. doi: 10.1074/jbc.M103554200, PMID 11369781
Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol 2008;13:447-51. doi: 10.1007/s10147-008-0773-3, PMID 18946756
Fu Y, Li H. Assessing clinical significance of serum CA15-3 and carcinoembryonic antigen (CEA) levels in breast cancer patients: A meta-analysis. Med Sci Monit 2016;22:3154-62. doi: 10.12659/ msm.896563, PMID 27596019
Park BW, Oh JW, Kim JH, Park SH, Kim KS, Kim JH, et al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 2008;19:675-81. doi: 10.1093/annonc/mdm538, PMID 18037623
Markowska J, Manys G, Kubaszewska M. Value of CA 125 as a marker of ovarian cancer. Eur J Gynaecol Oncol 1992;13:360-5. PMID 1516589
Kimura Y, Fujii T, Hamamoto K, Miyagawa N, Kataoka M, Iio A. Serum CA125 level is a good prognostic indicator in lung cancer. Br J Cancer 1990;62:676-8. doi: 10.1038/bjc.1990.355, PMID 2223590
Duk JM, Aalders JG, Fleuren GJ, de Bruijn HW. CA 125: A useful marker in endometrial carcinoma. Am J Obstet Gynecol 1986;155:1097- 102. doi: 10.1016/0002-9378(86)90358-3, PMID 3465243
Chi-Jung H, Jeng-Kai J, Shih-Ching C, Jen-Kou L, Shung-Haur Y. Serum CA125 concentration as a predictor of peritoneal dissemination of colorectal cancer in men and women. Medicine (Baltimore) 2016;95:e5177. doi: 10.1097/MD.0000000000005177
Agha-Hosseini F, Mirzaii-Dizgah I, Rahimi A, Seilanian-Toosi M. Correlation of serum and salivary CA125 levels in patients with breast cancer. J Contemp Dent Pract 2009;10:E001-8. PMID 20020075
Gaughran G, Aggarwal N, Shadbolt B, Stuart-Harris R. The utility of the tumor markers CA15.3, CEA, CA-125 and CA19.9 in metastatic breast cancer. Breast Cancer Manag 2020;9:BMT50. doi: 10.2217/bmt- 2020-0015
Zhao S, Mei Y, Wang J, Zhang K, Ma R. Different levels of CEA, CA153 and CA125 in milk and benign and malignant nipple discharge. PLoS One 2016;11:e0157639. doi: 10.1371/journal.pone.0157639, PMID 27327081
Published
How to Cite
Issue
Section
Copyright (c) 2023 URVASHEE DWIVEDI, ANURAG JAIN, FATIMA BHOPALWALA ALI, Mustafa Ali
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
